Tofacitinib linked to higher cardiovascular, cancer risks than TNF inhibitors in RA

Patients with rheumatoid arthritis who received tofacitinib demonstrated a greater risk for major adverse cardiovascular events and cancer than those treated with TNF inhibitors, according to data in The New England Journal of Medicine.
In the study — a safety trial ordered by the FDA following reports of increased lipid levels and cancer incidence associated with tofacitinib (Xeljanz,

Related Keywords

Minnesota ,United States ,Stevenr Ytterberg , ,Pfizer ,Drug Administration ,New England Journal ,Mayo Clinic ,Oral Rheumatoid Arthritis Trial ,